Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.48 |
| ▸ | VEGFA | P15692 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485356 | 0.91 | EGLN1 (0.49) | EGLN1VEGFAFLT1PARP1GRIN2B | |
| SCHEMBL3485402 | 0.90 | KDM4E (0.49) | EGLN1VEGFAFLT1PARP1GRIN2B | |
| SCHEMBL3485322 | 0.88 | CNR2 (0.47) | EGLN1VEGFAFLT1GRIN2BGRIN1 | |
| SCHEMBL3485269 | 0.88 | GRIN2B (0.47) | EGLN1VEGFAFLT1GRIN2BGRIN1 | |
| SCHEMBL3484844 | 0.87 | EGLN1 (0.60) | EGLN1VEGFAFLT1GRIN2BEGLN3 | |
| SCHEMBL3485085 | 0.86 | GRIN2B (0.51) | EGLN1VEGFAFLT1GRIN2BGRIN1 | |
| SCHEMBL3480614 | 0.84 | EGLN1 (0.60) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL3485404 | 0.83 | PARP1 (0.49) | PARP1GRIN2BGRIN1PIK3CDPIK3CA | |
| SCHEMBL3485425 | 0.82 | EGLN1 (0.48) | EGLN1VEGFAFLT1PARP1GRIN2B | |
| SCHEMBL3484818 | 0.81 | EGLN1 (0.60) | EGLN1VEGFAFLT1GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.